Notify me when Eversept Partners, LP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 103 | $1,783,428,441 | +$501,389,551 | -$311,136,457 | +$190,253,094 | VERA, GSK, UTHR, ABVX, NTRA | 13F-HR | 17 Feb 2026, 10:50 |
| Q3 2025 | 83 | $1,305,646,781 | +$405,231,058 | -$233,835,476 | +$171,395,582 | UTHR, GSK, NTRA, VERA, SNDX | 13F-HR | 14 Nov 2025, 11:34 |
| Q2 2025 | 67 | $992,228,456 | +$276,192,868 | -$185,904,332 | +$90,288,536 | NTRA, GSK, VERA, RVTY, PCVX | 13F-HR | 14 Aug 2025, 11:41 |
| Q1 2025 | 55 | $883,687,039 | +$228,856,792 | -$231,300,407 | -$2,443,615 | NTRA, GSK, HCA, SNDX, VERA | 13F-HR | 15 May 2025, 10:41 |
| Q4 2024 | 62 | $969,066,469 | +$168,745,437 | -$400,593,410 | -$231,847,973 | NTRA, GSK, VERA, INSP, HCA | 13F-HR | 14 Feb 2025, 10:13 |
| Q3 2024 | 65 | $1,303,596,522 | +$145,188,874 | -$326,148,343 | -$180,959,469 | GSK, NTRA, VERA, INSM, SNDX | 13F-HR | 14 Nov 2024, 09:08 |
| Q2 2024 | 72 | $1,306,688,227 | +$256,257,689 | -$270,238,491 | -$13,980,802 | GSK, NTRA, INSM, TEVA, UTHR | 13F-HR | 14 Aug 2024, 09:03 |
| Q1 2024 | 68 | $1,338,095,549 | +$248,505,649 | -$158,505,705 | +$89,999,944 | NTRA, GSK, INSP, TEVA, VERA | 13F-HR | 15 May 2024, 08:40 |
| Q4 2023 | 55 | $1,019,780,533 | +$200,202,063 | -$184,000,271 | +$16,201,792 | NTRA, GSK, SNDX, INSP, TEVA | 13F-HR | 14 Feb 2024, 08:50 |
| Q3 2023 | 61 | $900,715,192 | +$165,102,013 | -$149,989,603 | +$15,112,410 | GSK, NTRA, TEVA, UTHR, INSP | 13F-HR | 14 Nov 2023, 14:07 |
| Q2 2023 | 66 | $946,893,078 | +$185,367,863 | -$324,331,202 | -$138,963,339 | NTRA, GSK, TEVA, UTHR, HZNP | Restatement | 08 Nov 2023, 14:50 |
| Q1 2023 | 58 | $1,112,501,187 | +$278,423,548 | -$230,984,486 | +$47,439,062 | NTRA, GSK, HZNP, TEVA, UTHR | Restatement | 08 Nov 2023, 14:48 |
| Q4 2022 | 3 | $342,366 | $0 | $0 | $0 | ELDN, SNDA, BOLT | New Holdings | 08 Nov 2023, 14:46 |
| Q4 2022 | 62 | $1,051,612,933 | +$334,553,429 | -$264,947,922 | +$69,605,507 | GSK, HZNP, NTRA, SNY, UTHR | Restatement | 08 Nov 2023, 14:44 |
| Q3 2022 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:42 | |
| Q3 2022 | 60 | $843,153,820 | +$230,222,677 | -$364,330,367 | -$134,107,690 | BHVN, GSK, HZNP, NTRA, UTHR | Restatement | 08 Nov 2023, 14:40 |
| Q2 2022 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:38 | |
| Q2 2022 | 65 | $1,023,939,921 | +$344,482,609 | -$265,574,004 | +$78,908,605 | BHVN, UTHR, HZNP, GSK, AZN | Restatement | 08 Nov 2023, 14:37 |
| Q1 2022 | 76 | $1,084,513,902 | +$253,982,943 | -$304,515,350 | -$50,532,407 | CYH, BHVN, HZNP, GSK, UTHR | Restatement | 08 Nov 2023, 14:35 |
| Q4 2021 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:33 | |
| Q4 2021 | 90 | $1,201,454,859 | +$239,172,339 | -$280,766,349 | -$41,594,010 | HZNP, CYH, UTHR, DHR, AZN | Restatement | 08 Nov 2023, 14:31 |
| Q3 2021 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:29 | |
| Q3 2021 | 88 | $1,245,968,450 | +$384,301,715 | -$228,274,696 | +$156,027,019 | UTHR, ASND, CYH, HZNP, XLRN | Restatement | 08 Nov 2023, 14:28 |
| Q2 2021 | 69 | $1,079,804,387 | +$243,691,405 | -$384,354,136 | -$140,662,731 | UTHR, AMRN, ARKG, HZNP, AZN | Restatement | 08 Nov 2023, 14:26 |
| Q1 2021 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:23 | |
| Q1 2021 | 74 | $1,220,549,007 | +$492,317,614 | -$154,511,430 | +$337,806,184 | AMRN, UTHR, ARKG, ALXN, HZNP | Restatement | 08 Nov 2023, 14:21 |
| Q4 2020 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:15 | |
| Q4 2020 | 58 | $832,671,186 | +$413,441,713 | -$144,996,285 | +$268,445,428 | AMRN, UTHR, ALXN, TGTX, AZN | Restatement | 08 Nov 2023, 14:13 |
| Q3 2020 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:10 | |
| Q3 2020 | 47 | $444,111,870 | +$109,486,307 | -$284,398,431 | -$174,912,124 | HZNP, AMRN, TGTX, ASND, UTHR | Restatement | 08 Nov 2023, 13:56 |
| Q2 2020 | 63 | $605,460,197 | +$264,759,940 | -$180,659,518 | +$84,100,422 | HZNP, TGTX, AMRN, BHVN, ASND | Restatement | 08 Nov 2023, 13:52 |
| Q1 2020 | 55 | $379,778,019 | +$162,601,178 | -$180,222,305 | -$17,621,127 | ZGNX, DHR, ASND, TGTX, APLS | Restatement | 08 Nov 2023, 13:50 |
| Q4 2019 | 67 | $491,876,322 | +$179,692,008 | -$68,277,193 | +$111,414,815 | GSK, ENSG, DHR, ASND, ZGNX | Restatement | 08 Nov 2023, 13:47 |
| Q3 2019 | 53 | $319,128,210 | +$99,043,742 | -$97,025,842 | +$2,017,900 | GSK, ENSG, DHR, ZGNX, ASND | Restatement | 08 Nov 2023, 13:45 |
| Q2 2019 | 59 | $350,006,420 | +$77,426,726 | -$81,970,455 | -$4,543,729 | RCM, AMRN, GSK, ZGNX, DHR | Restatement | 08 Nov 2023, 13:39 |
| Q1 2019 | 49 | $337,795,907 | +$148,126,314 | -$32,175,750 | +$115,950,564 | AMRN, GSK, RCM, ZGNX, DHR | Restatement | 08 Nov 2023, 13:38 |
| Q4 2018 | 53 | $180,328,680 | +$52,404,977 | -$36,532,042 | +$15,872,935 | ZGNX, GSK, RCM, AMRN, SNY | Restatement | 08 Nov 2023, 13:36 |
| Q3 2018 | 57 | $199,177,191 | +$63,852,902 | -$76,160,724 | -$12,307,822 | ZGNX, RCM, AMRN, SNY, GSK | Restatement | 08 Nov 2023, 13:33 |
| Q2 2018 | 67 | $204,139,040 | +$45,260,598 | -$52,768,015 | -$7,507,417 | QCP, RCM, AERI, RDUS, GSK | Restatement | 08 Nov 2023, 13:31 |
| Q1 2018 | 54 | $198,356,995 | +$82,975,604 | -$46,845,800 | +$36,129,804 | QCP, RCM, RDUS, AERI, ABLX | Restatement | 08 Nov 2023, 13:29 |
| Q4 2017 | 45 | $149,779,862 | $0 | $0 | $0 | ARRY, AERI, ZGNX, VRTX, SNY | Restatement | 08 Nov 2023, 13:26 |